Pancreatic adenocarcinoma: Beyond first line, where are we?

doi:10.3748/wjg.v27.i17.1847

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7935)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

614

WORD

268

HTML

4183

Figures (1-2)

459

Tables (1-2)

328

Sum=5852

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

323

Download

558

Sum=881

Publishing Process of This Article

Item

Count

Browse

486

Download

716

Sum=1202

May 7, 2021 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Evidence Review

World J Gastroenterol. May 7, 2021; 27(17): 1847-1863
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.1847

Open in New Tab Full Size Figure Download Figure

Figure 1 Current therapeutic possibilities for metastatic pancreatic ductal adenocarcinoma. NabP: Nab-paclitaxel; Nal-IRI: Nanoliposomal irinotecan; 5FU: 5-Fluorouracil; FOLFIRI: 5-Fluorouracil + irinotecan; FOLFOX: 5-fluorouracil + leucovorin + oxaliplatin; OFF: Oxaliplatin + 5-fluorouracil + folinic acid; CapeOx: Capecitabine + oxaliplatin; MSI-H: Microsatellite instability high; dMMR: DNA mismatch repair deficiency; Clinical trials?: Evaluate the availability of clinical trials suitable for the patient.

Open in New Tab Full Size Figure Download Figure

Figure 2 Main targeted drugs under study for patients with advanced pancreatic ductal adenocarcinoma. EGFR: Epidermal growth factor receptor; TGFβ: Transforming growth factor β; APC: Antigen presenting cells; PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death protein ligand 1; CAR-T: Chimeric antigen receptor T cells.

Citation: Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863
URL: https://www.wjgnet.com/1007-9327/full/v27/i17/1847.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i17.1847